Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Ardelyx, Inc.NASDAQ: ARDX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents broadly unchanged from a year ago

Cash & equivalents stood at $31.21M at the end of Q1 FY2026, up 1.3% from a year earlier and down 54.1% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.

Context

  • Cash & equivalents amounted to 6.2% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.21M-54.1% QoQ
Last fiscal yearDec 2025
$68M+4.7% YoY
Year agoMar 2025
$30.81M+1.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.3%——
1 year+4.7%——
3-year CAGR-10.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
68M USD
Year-over-year change
+4.7%
4-year CAGR
-1.6%

Cash & Equivalents vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's Mar 2026 cash & equivalents of $31.21M is the 4th highest of the 5 companies compared; the peer median is $137.2M.
  • Its year-over-year change of +1.3% is the 4th highest of 5, against a peer median of +65.7%.
  • Cash & equivalents amounts to 6.2% of total assets for ARDX, versus a peer median of 36.7%.
ARDX Competitors Peer median
Cash & Equivalents for ARDX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MAZEMaze Therapeutics, Inc.Mar 2026$198.77M -32.5%+23.7%47.4%
AKBAAkebia Therapeutics, Inc.Mar 2026$162.64M +43.5%+26.9%44.9%
XERSXeris Biopharma Holdings, Inc.Mar 2026$111.75M +91.2%-3.1%28.5%
ARDXArdelyx, Inc.Mar 2026$31.21M +1.3%-10.9%6.2%
DMACDiaMedica Therapeutics Inc.Mar 2026$4.87M +88.0%+49.0%9.2%
Peer median (excluding ARDX) $137.2M+65.7%+25.3%36.7%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents72.43M96.14M21.47M64.93M68M
Short-term Investments44.26M27.77M162.83M185.17M196.69M
Net Receivables502K7.73M22.03M57.71M71.85M
Inventory03.28M12.45M21.17M17.74M
Other Current Assets15.11M8.41M11.1M13.57M
Total Current Assets133.65M153.6M246.11M356.45M382.32M
Property, Plant & Equipment (Net)15.11M10.52M6.6M3.88M6.98M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.15M25.95M44.87M75.43M112.31M
Total Non-current Assets16.26M36.46M51.47M79.3M119.29M
Total Assets149.91M190.07M297.58M435.75M501.6M
Account Payables4.28M10.86M11.14M16M19.24M
Short-term Debt32.26M26.71M001.48M
Tax Payables00000
Deferred Revenue04.21M7.18M10.69M1.21M
Other Current Liabilities1.24M10.09M15.04M21.48M66.69M
Total Current Liabilities52.82M65.6M50.39M77.83M88.61M
Long-term Debt0049.82M150.85M206.48M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)09.03M8.64M7.23M39.58M
Other Non-current Liabilities4.73M11.25M20.18M25.53M(3.64M)
Total Non-current Liabilities14.48M26.13M80.37M184.64M246.05M
Total Liabilities67.3M91.74M130.76M262.47M334.66M
Common Stock13K20K23K24K24K
Retained Earnings(712.93M)(780.14M)(846.2M)(885.34M)(946.94M)
Accumulated OCI(6K)(54K)224K57K198K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity82.62M98.33M166.82M173.29M166.95M
Total Debt45.5M36.46M55.98M153.44M211.6M
Net Debt(26.92M)(59.68M)34.51M88.51M143.6M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.